About Transcription factor E2F3
Transcription factor E2F3 (E2F3) is a protein
from Homo sapiens identified by UniProt accession
O00716, 465 residues long.
MolForge cross-references it against 0 known binders and
203 disease associations.
Target properties
| Protein name | Transcription factor E2F3 |
| UniProt accession | O00716 |
| Gene | E2F3 |
| Organism | Homo sapiens |
| Length | 465 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (203)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.47
- serum alanine aminotransferase measurement · score 0.41
- cystatin C measurement · score 0.35
- serum albumin measurement · score 0.35
- creatinine measurement · score 0.35
- body mass index · score 0.34
- triglyceride measurement · score 0.34
- body fat percentage · score 0.34
- BMI-adjusted waist-hip ratio · score 0.34
- glomerular filtration rate · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00716-F1 | alphafold | PREDICTED | 59.46 | — |
Amino-acid sequence (465 residues)
MRKGIQPALE QYLVTAGGGE GAAVVAAAAA ASMDKRALLA SPGFAAAAAA AAAPGAYIQI LTTNTSTTSC SSSLQSGAVA AGPLLPSAPG AEQTAGSLLY TTPHGPSSRA GLLQQPPALG RGGSGGGGGP PAKRRLELGE SGHQYLSDGL KTPKGKGRAA LRSPDSPKTP KSPSEKTRYD TSLGLLTKKF IQLLSQSPDG VLDLNKAAEV LKVQKRRIYD ITNVLEGIHL IKKKSKNNVQ WMGCSLSEDG GMLAQCQGLS KEVTELSQEE KKLDELIQSC TLDLKLLTED SENQRLAYVT YQDIRKISGL KDQTVIVVKA PPETRLEVPD SIESLQIHLA STQGPIEVYL CPEETETHSP MKTNNQDHNG NIPKPASKDL ASTNSGHSDC SVSMGNLSPL ASPANLLQQT EDQIPSNLEG PFVNLLPPLL QEDYLLSLGE EEGISDLFDA YDLEKLPLVE DFMCS
Explore Transcription factor E2F3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets